$PLRZ News
Last published 2d ago
- 2d agoPLRZPOLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLANGlobeNewswireTEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that its Board of Directors (the “Board”) has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately.
- 2d agoPLRZPOLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLANGlobeNewswireTEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative
- 2w agoPLRZPolyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy BlockerGlobeNewswireAll 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"),
- 2mo agoPLRZPolyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private PlacementGlobeNewswireRAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today
- 2mo agoPLRZPolyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private PlacementGlobeNewswireRAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today
- 2mo agoPLRZPolyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy StudyGlobeNewswireRaanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative
- 2mo agoPLRZPolyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient EnrollmentGlobeNewswirePolyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ)
- 4mo agoPLRZPolyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical TrialGlobeNewswireRaanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative
- 4mo agoPLRZPolyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical TrialGlobeNewswireRaanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative
- 4mo agoPLRZPolyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformGlobeNewswireRaanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,
- 4mo agoPLRZPolyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory PathwayGlobeNewswireNew performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function Raanana,
- 5mo agoPLRZPolyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery TechnologyGlobeNewswireRaanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,
- 5mo agoPLRZPolyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ TrialGlobeNewswireRaanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,
- 6mo agoPLRZPolyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical TrialGlobeNewswireRaanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,
- 6mo agoPLRZPulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable ProtectionPR NewswireRecent World Health Organization reports of Hantavirus clusters, including clusters of severe acute respiratory illness, have once again served as a...
- 6mo agoPLRZPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformGlobeNewswireRaanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,
- 6mo agoPLRZPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformGlobeNewswireRaanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels,
- 7mo agoPLRZPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsGlobeNewswireRAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the closing of
- 7mo agoPLRZPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementGlobeNewswireRAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has
- 7mo agoPLRZPolyrizon Provides 2025 and Recent HighlightsGlobeNewswireRaanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and
- 7mo agoPLRZPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025GlobeNewswireRaanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced
- 7mo agoPLRZPolyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility ApplicationsGlobeNewswireThe Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, March 24, 2026
- 8mo agoPLRZPolyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical StudyGlobeNewswireRaanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today
- 8mo agoPLRZPolyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference ProductGlobeNewswireRaanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced
- 8mo agoPLRZMoonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy BlockerPR NewswireEarly in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the...
- 9mo agoPLRZPolyrizon Intends to Secure Controlling Stake in Profitable Private Jet OperatorGlobeNewswireThe Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana,
- 9mo agoCMNDPLRZPolyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen FormulationGlobeNewswireCollaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE
- 9mo agoCMNDPLRZClearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAIGlobeNewswireCollaboration aims to enhance bioavailability and support clinical advancement of Clearmind's lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE NEWSWIRE) --
- 9mo agoPLRZPolyrizon Intends to Acquire 51% Stake in Global Private Aviation CompanyGlobeNewswireThe Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana,
- 9mo agoPLRZPolyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy BlockerGlobeNewswireExecuted in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development Raanana, Israel,
- 10mo agoPLRZPolyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance SheetGlobeNewswireCompany Remains Fully Committed to Advancing Its Core Intranasal Medical Pipeline, alongside examining new opportunities including in fields of aviation, AI and defense Raanana, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE)
- 10mo agoPLRZPolyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™GlobeNewswireAs part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd.
- 10mo agoPLRZPolyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard ComparatorGlobeNewswireRaanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions
- 10mo agoPLRZAs Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and UnvaccinatedGlobeNewswireRaanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a mutated strain of influenza A is driving most cases, sparking concerns about a potentially tough
- 10mo agoPLRZPolyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance SheetGlobeNewswireCompany to Continue Advancing Product Development and Regulatory Progress of Its Core Medical Pipeline Raanana, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or
- 10mo agoPLRZPolyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold VirusesGlobeNewswireThe PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing
- 11mo agoPLRZPolyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel ProgramGlobeNewswireRa'anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced new results
- 11mo agoPLRZPolyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal SprayGlobeNewswireRa'anana, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announces that it has
- 11mo agoPLRZFrom Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal ProtectionGlobeNewswireRa'anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to
- 11mo agoPLRZPolyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone productGlobeNewswireSuperior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra'anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or
- 11mo agoPLRZPolyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray PlatformGlobeNewswireRa'anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain
- 1y agoPLRZPolyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming FormulationGlobeNewswireIn-Vitro Data Confirms Strong Protection Against H1N1 Influenza via Physical Barrier Mechanism Ra'anana, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a
- 1y agoPLRZPolyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking EfficacyGlobeNewswireRa'anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain
- 1y agoPLRZPolyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy BlockerGlobeNewswireRa'anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced the
- 1y agoPLRZPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudyGlobeNewswireRa'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging
- 1y agoPLRZPolyrizon Regains Compliance with Nasdaq Listing RequirementsGlobeNewswireRa'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has
- 1y agoPLRZPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudyGlobeNewswireRa'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging
- 1y agoPLRZPolyrizon Retains Nasdaq Listing Following Hearings PanelGlobeNewswireRaanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels,
- 1y agoPLRZPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsGlobeNewswireRa'anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a biotechnology company developing intranasal drug delivery systems, today announced encouraging
- 1y agoPLRZPolyrizon Announces Receipt of Nasdaq Delisting NoticeGlobeNewswireRaanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels,